{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:25:04Z","timestamp":1790490304092,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,12,10]],"date-time":"2008-12-10T00:00:00Z","timestamp":1228867200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s10549-008-0260-6","type":"journal-article","created":{"date-parts":[[2008,12,9]],"date-time":"2008-12-09T17:30:12Z","timestamp":1228843812000},"page":"357-364","source":"Crossref","is-referenced-by-count":127,"title":["Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study"],"prefix":"10.1007","volume":"117","author":[{"given":"Deepa","family":"Wadhwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Fallah-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debjani","family":"Grenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Krahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tielan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roien","family":"Ahmadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danica","family":"Lister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh C.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Barac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder S.","family":"Jassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,12,10]]},"reference":[{"key":"260_CR1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM200002243420807","volume":"342","author":"K Armstrong","year":"2000","unstructured":"Armstrong K, Eisen A, Weber B (2000) Primary care: assessing the risk of breast cancer. N Engl J Med 342:564\u2013571","journal-title":"N Engl J Med"},{"key":"260_CR2","unstructured":"American Heart Association. http:\/\/www.americanheart.com\/presenter.jhtml?identifier=120000"},{"key":"260_CR3","unstructured":"American Cancer Society. http:\/\/www.cancer.org\/docroot\/home.index.asp"},{"key":"260_CR4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc1360","volume":"4","author":"A Gschwind","year":"2004","unstructured":"Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4:361\u2013370","journal-title":"Nat Rev Cancer"},{"key":"260_CR5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235:177\u2013182","journal-title":"Science"},{"key":"260_CR6","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","volume":"89","author":"P Carter","year":"1992","unstructured":"Carter P, Presta L, Gorman CM et al (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285\u20134289","journal-title":"Proc Natl Acad Sci USA"},{"key":"260_CR7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer. J Clin Oncol 20:719\u2013726","journal-title":"J Clin Oncol"},{"key":"260_CR8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S et al (2001) Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer. A phase III, multinational, randomized control trial. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"260_CR9","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"M Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart M, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med 353:1659\u20131672","journal-title":"N Engl J Med"},{"key":"260_CR10","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med 353:1673\u20131684","journal-title":"N Engl J Med"},{"key":"260_CR11","doi-asserted-by":"crossref","unstructured":"Slamon D, Eirmann W, Robert N et\u00a0al (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzuman (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94:S5","DOI":"10.1158\/1538-7445.SABCS15-S5-04"},{"key":"260_CR12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JCO.2004.01.120","volume":"22","author":"EA Perez","year":"2004","unstructured":"Perez EA, Rodeheffer R (2004) Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22:322\u2013329","journal-title":"J Clin Oncol"},{"key":"260_CR13","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"E Tan-Chiu","year":"2005","unstructured":"Tan-Chiu E, Yothers G, Romond E et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811\u20137819","journal-title":"J Clin Oncol"},{"key":"260_CR14","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Vooletich MT, Durand JB et al (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23:7820\u20137826","journal-title":"J Clin Oncol"},{"key":"260_CR15","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","volume":"24","author":"V Guarneri","year":"2006","unstructured":"Guarneri V, Lenihan DJ, Valero V et al (2006) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Care Centre experience. J Clin Oncol 24:4107\u20134115","journal-title":"J Clin Oncol"},{"key":"260_CR16","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/01.CIR.0000080946.42225.4D","volume":"108","author":"FJ Klocke","year":"2003","unstructured":"Klocke FJ, Baird MG, Lorell BH et al (2003) ACC\/AHA\/ASNC guidelines for the clinical use of cardiac radionuclide imaging\u2014Executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (ACC\/AHA\/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation 108:1404\u20131418","journal-title":"Circulation"},{"key":"260_CR17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0894-7317(89)80013-6","volume":"2","author":"NM Schiller","year":"1989","unstructured":"Schiller NM, Shah PM, Crawford M et al (1989) Recommendations for quantification of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, subcommittee on quantization of two-dimensional echocardiograms. J Am Soc Echocardiogr 2:358\u2013367","journal-title":"J Am Soc Echocardiogr"},{"key":"260_CR18","doi-asserted-by":"crossref","first-page":"10640","DOI":"10.1200\/JCO.2005.03.4009","volume":"24","author":"HL McArthur","year":"2006","unstructured":"McArthur HL, Barnett J, Chia S (2006) A population-based study of trastuzumab-mediated cardiotoxicity among early stage breast cancer patients treated with adjuvant trastuzumab. J Clin Oncol 24:10640 (Abstract)","journal-title":"J Clin Oncol"},{"key":"260_CR19","first-page":"600","volume":"7","author":"MS Ewer","year":"2007","unstructured":"Ewer MS, O\u2019Shaughnessy JA (2007) Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer 7:600\u2013607","journal-title":"Clin Breast Cancer"},{"key":"260_CR20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1067\/mhj.2001.118115","volume":"142","author":"JH Silber","year":"2001","unstructured":"Silber JH, Cnaan A, Clark BJ et al (2001) Design and baseline characteristics for the ace inhibitor after anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors. Am Heart J 142:577\u2013585","journal-title":"Am Heart J"},{"key":"260_CR21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0002-8703(95)90061-6","volume":"129","author":"RE Shaddy","year":"1995","unstructured":"Shaddy RE, Olsen SL, Bristow MR et al (1995) Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J 129:197\u2013199","journal-title":"Am Heart J"},{"key":"260_CR22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1200\/JCO.1984.2.2.112","volume":"2","author":"MS Ewer","year":"1984","unstructured":"Ewer MS, Ali MK, MacKay B et al (1984) A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol 2:112\u2013117","journal-title":"J Clin Oncol"},{"key":"260_CR23","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","volume":"339","author":"PK Singal","year":"1998","unstructured":"Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900\u2013905","journal-title":"N Engl J Med"},{"key":"260_CR24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1388-9842(00)00096-9","volume":"2","author":"K Rajappan","year":"2000","unstructured":"Rajappan K, Bellenger NG, Anderson L et al (2000) The role of cardiovascular magnetic resonance in heart failure. Eur J Heart Failure 2:241\u2013252","journal-title":"Eur J Heart Failure"},{"key":"260_CR25","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJM200011163432003","volume":"343","author":"RJ Kim","year":"2000","unstructured":"Kim RJ, Wu E, Rafael A et al (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343:1445\u20131453","journal-title":"N Engl J Med"},{"key":"260_CR26","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.jacc.2006.08.017","volume":"48","author":"HN Skouri","year":"2006","unstructured":"Skouri HN, Dec GW, Friedrich MG et al (2006) Noninvasive imaging in myocarditis. J Am Coll Cardiol 48:2085\u20132093","journal-title":"J Am Coll Cardiol"},{"key":"260_CR27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1532-429X-10-5","volume":"10","author":"N Fallah-Rad","year":"2008","unstructured":"Fallah-Rad N, Lytwyn M, Fang T et al (2008) Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 10:5","journal-title":"J Cardiovasc Magn Reson"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-008-0260-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0260-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:29:04Z","timestamp":1559233744000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-008-0260-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,10]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["260"],"URL":"https:\/\/doi.org\/10.1007\/s10549-008-0260-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,10]]}}}